KA/EN
Register
Medicines reference
Search
Search
Product

Simparica

Favourites

Sarolaner · Zoetis

6 forms: chewable tablet. In force in Georgia: 6 of 6 (veterinary register).

Forms and doses6 of 6 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Choose species and weight; the matching row will be highlighted.
Form Species Weight Dose Frequency Georgia
5 mg, Chewable tablet · Cat Any weight Cat Any weight No dose for this species
This sarolaner product is for dogs only. Do not use it in cats.
 - Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა - 5მგ საღეჭი ტაბლეტი 1,3-2,5კგ ძაღლებისთვის
№ 165-11
Verified on: 15 Oct 2026
5 mg, Chewable tablet · Dog 1.3–2.5 kg Dog 1.3–2.5 kg 1 tablet
a dose of 2–4 mg/kg bodyweight SIMPARICA should not be used in dogs less than 6 months of age not recommended
 · monthly		 monthly Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა - 5მგ საღეჭი ტაბლეტი 1,3-2,5კგ ძაღლებისთვის
№ 165-11
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Simparica 5 mg, Chewable tablet

sarolaner 5 mg, chewable tablet for dogs 1.3-2.5 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.4/10
Very good
vetman assessment

Simparica

5 mg, sarolaner 5 mg, chewable tablet for dogs 1.3-2.5 kg
Assessed clinical scopeDog · Full labelled canine scope for monthly treatment and control of susceptible fleas, ticks and mites · By mouth
Care settingMonthly weight-band chewable ectoparasite control after age, neurologic and parasite-risk assessment
vetman score 8.4/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 165-11 · Verified on 15 Oct 2026

A strongly supported monthly canine ectoparasiticide with excellent efficacy and convenience; the main limitation is the class-wide neurological risk and jurisdiction-dependent age/breeding restrictions.

Regulatory and scientific credibility9.0/10

Every exact strength is registered in Georgia and the product has mature current EU/UK and FDA authorisations with detailed public labels.

Clinical efficacy9.0/10

Randomized controlled laboratory and multicentre field studies show high and persistent monthly efficacy against labelled flea, tick and mite targets, with clinically useful speed of kill.

Safety and tolerability7.0/10

Safety is well characterised, but sarolaner is an isoxazoline and rare tremor, ataxia or seizures can occur even without prior history; pregnancy/breeding safety and young-puppy rules differ by jurisdiction.

Clinical practicality9.0/10

One palatable chew once monthly across six clear weight bands is highly practical; accurate weighing and use of the correct whole-tablet band remain essential.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Isoxazolines can be associated with tremor, ataxia and seizures, including in dogs without a prior seizure history; use particular caution with pre-existing neurologic disease.
  • Use only in dogs and only the correct whole-tablet weight band; do not split or extrapolate a strength to another species or band.
  • Age, pregnancy, lactation and breeding restrictions differ between current EU/UK and US labels; follow the locally applicable exact label and document the benefit-risk decision.
  • Confirm the parasite target and maintain the labelled monthly schedule; reassess breakthrough infestation, adherence and environmental reinfection rather than shortening intervals empirically.
Assessment sources
  1. VMD SPC 20242024
  2. FDA 20242024
  3. Simparica US flea field trial2016
  4. Simparica tick dose trials2016
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Sarolaner5 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა - 5მგ საღეჭი ტაბლეტი 1,3-2,5კგ ძაღლებისთვის
№ 165-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-452
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
No dose for this species
This sarolaner product is for dogs only. Do not use it in cats.
 Cat Any weight By mouth - Product label (SPC)
1 tablet
a dose of 2–4 mg/kg bodyweight SIMPARICA should not be used in dogs less than 6 months of age not recommended
 Dog 1.3–2.5 kg By mouth monthly Product label (SPC)
10 mg, Chewable tablet · Cat Any weight Cat Any weight No dose for this species
This sarolaner product is for dogs only. Do not use it in cats.
 - Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა - 10მგ საღეჭი ტაბლეტი 2.5-5კგ ძაღლებისთვის
№ 164-11
Verified on: 15 Oct 2026
10 mg, Chewable tablet · Dog 2.5–5 kg Dog 2.5–5 kg 1 tablet
Give 1 whole 10 mg sarolaner chewable tablet monthly to a dog weighing over 2.5 kg up to 5 kg, providing 2–4 mg/kg. Do not divide the tablet. Use in pregnant, lactating, or breeding dogs is not recommended.
 · monthly		 monthly Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა - 10მგ საღეჭი ტაბლეტი 2.5-5კგ ძაღლებისთვის
№ 164-11
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Simparica 10 mg, Chewable tablet

sarolaner 10 mg, chewable tablet for dogs 2.5-5 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.4/10
Very good
vetman assessment

Simparica

10 mg, sarolaner 10 mg, chewable tablet for dogs 2.5-5 kg
Assessed clinical scopeDog · Full labelled canine scope for monthly treatment and control of susceptible fleas, ticks and mites · By mouth
Care settingMonthly weight-band chewable ectoparasite control after age, neurologic and parasite-risk assessment
vetman score 8.4/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 164-11 · Verified on 15 Oct 2026

A strongly supported monthly canine ectoparasiticide with excellent efficacy and convenience; the main limitation is the class-wide neurological risk and jurisdiction-dependent age/breeding restrictions.

Regulatory and scientific credibility9.0/10

Every exact strength is registered in Georgia and the product has mature current EU/UK and FDA authorisations with detailed public labels.

Clinical efficacy9.0/10

Randomized controlled laboratory and multicentre field studies show high and persistent monthly efficacy against labelled flea, tick and mite targets, with clinically useful speed of kill.

Safety and tolerability7.0/10

Safety is well characterised, but sarolaner is an isoxazoline and rare tremor, ataxia or seizures can occur even without prior history; pregnancy/breeding safety and young-puppy rules differ by jurisdiction.

Clinical practicality9.0/10

One palatable chew once monthly across six clear weight bands is highly practical; accurate weighing and use of the correct whole-tablet band remain essential.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Isoxazolines can be associated with tremor, ataxia and seizures, including in dogs without a prior seizure history; use particular caution with pre-existing neurologic disease.
  • Use only in dogs and only the correct whole-tablet weight band; do not split or extrapolate a strength to another species or band.
  • Age, pregnancy, lactation and breeding restrictions differ between current EU/UK and US labels; follow the locally applicable exact label and document the benefit-risk decision.
  • Confirm the parasite target and maintain the labelled monthly schedule; reassess breakthrough infestation, adherence and environmental reinfection rather than shortening intervals empirically.
Assessment sources
  1. VMD SPC 20242024
  2. FDA 20242024
  3. Simparica US flea field trial2016
  4. Simparica tick dose trials2016
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Sarolaner10 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა - 10მგ საღეჭი ტაბლეტი 2.5-5კგ ძაღლებისთვის
№ 164-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-452
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
No dose for this species
This sarolaner product is for dogs only. Do not use it in cats.
 Cat Any weight By mouth - Product label (SPC)
1 tablet
Give 1 whole 10 mg sarolaner chewable tablet monthly to a dog weighing over 2.5 kg up to 5 kg, providing 2–4 mg/kg. Do not divide the tablet. Use in pregnant, lactating, or breeding dogs is not recommended.
 Dog 2.5–5 kg By mouth monthly Product label (SPC)
20 mg, Chewable tablet · Cat Any weight Cat Any weight No dose for this species
This sarolaner product is for dogs only. Do not use it in cats.
 - Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა - 20მგ საღეჭი ტაბლეტის 5-10კგ ძაღლებისთვის
№ 157-11
Verified on: 15 Oct 2026
20 mg, Chewable tablet · Dog 5–10 kg Dog 5–10 kg 1 tablet
Simparica 20 mg Chewable Tablets for Dogs >5–10 kg not recommended
 · monthly		 monthly Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა - 20მგ საღეჭი ტაბლეტის 5-10კგ ძაღლებისთვის
№ 157-11
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Simparica 20 mg, Chewable tablet

sarolaner 20 mg, chewable tablet for dogs 5-10 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.4/10
Very good
vetman assessment

Simparica

20 mg, sarolaner 20 mg, chewable tablet for dogs 5-10 kg
Assessed clinical scopeDog · Full labelled canine scope for monthly treatment and control of susceptible fleas, ticks and mites · By mouth
Care settingMonthly weight-band chewable ectoparasite control after age, neurologic and parasite-risk assessment
vetman score 8.4/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 157-11 · Verified on 15 Oct 2026

A strongly supported monthly canine ectoparasiticide with excellent efficacy and convenience; the main limitation is the class-wide neurological risk and jurisdiction-dependent age/breeding restrictions.

Regulatory and scientific credibility9.0/10

Every exact strength is registered in Georgia and the product has mature current EU/UK and FDA authorisations with detailed public labels.

Clinical efficacy9.0/10

Randomized controlled laboratory and multicentre field studies show high and persistent monthly efficacy against labelled flea, tick and mite targets, with clinically useful speed of kill.

Safety and tolerability7.0/10

Safety is well characterised, but sarolaner is an isoxazoline and rare tremor, ataxia or seizures can occur even without prior history; pregnancy/breeding safety and young-puppy rules differ by jurisdiction.

Clinical practicality9.0/10

One palatable chew once monthly across six clear weight bands is highly practical; accurate weighing and use of the correct whole-tablet band remain essential.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Isoxazolines can be associated with tremor, ataxia and seizures, including in dogs without a prior seizure history; use particular caution with pre-existing neurologic disease.
  • Use only in dogs and only the correct whole-tablet weight band; do not split or extrapolate a strength to another species or band.
  • Age, pregnancy, lactation and breeding restrictions differ between current EU/UK and US labels; follow the locally applicable exact label and document the benefit-risk decision.
  • Confirm the parasite target and maintain the labelled monthly schedule; reassess breakthrough infestation, adherence and environmental reinfection rather than shortening intervals empirically.
Assessment sources
  1. VMD SPC 20242024
  2. FDA 20242024
  3. Simparica US flea field trial2016
  4. Simparica tick dose trials2016
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Sarolaner20 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა - 20მგ საღეჭი ტაბლეტის 5-10კგ ძაღლებისთვის
№ 157-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-452
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
No dose for this species
This sarolaner product is for dogs only. Do not use it in cats.
 Cat Any weight By mouth - Product label (SPC)
1 tablet
Simparica 20 mg Chewable Tablets for Dogs >5–10 kg not recommended
 Dog 5–10 kg By mouth monthly Product label (SPC)
40 mg, Chewable tablet · Cat Any weight Cat Any weight No dose for this species
This sarolaner product is for dogs only. Do not use it in cats.
 - Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა -40მგ საღეჭი ტაბლეტი 10-20კგ ძაღლებისთვის
№ 163-11
Verified on: 15 Oct 2026
40 mg, Chewable tablet · Dog 10–20 kg Dog 10–20 kg 1 tablet
Simparica 40 mg Chewable Tablets for Dogs >10–20 kg not recommended
 · monthly		 monthly Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა -40მგ საღეჭი ტაბლეტი 10-20კგ ძაღლებისთვის
№ 163-11
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Simparica 40 mg, Chewable tablet

sarolaner 40 mg, chewable tablet for dogs 10-20 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.4/10
Very good
vetman assessment

Simparica

40 mg, sarolaner 40 mg, chewable tablet for dogs 10-20 kg
Assessed clinical scopeDog · Full labelled canine scope for monthly treatment and control of susceptible fleas, ticks and mites · By mouth
Care settingMonthly weight-band chewable ectoparasite control after age, neurologic and parasite-risk assessment
vetman score 8.4/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 163-11 · Verified on 15 Oct 2026

A strongly supported monthly canine ectoparasiticide with excellent efficacy and convenience; the main limitation is the class-wide neurological risk and jurisdiction-dependent age/breeding restrictions.

Regulatory and scientific credibility9.0/10

Every exact strength is registered in Georgia and the product has mature current EU/UK and FDA authorisations with detailed public labels.

Clinical efficacy9.0/10

Randomized controlled laboratory and multicentre field studies show high and persistent monthly efficacy against labelled flea, tick and mite targets, with clinically useful speed of kill.

Safety and tolerability7.0/10

Safety is well characterised, but sarolaner is an isoxazoline and rare tremor, ataxia or seizures can occur even without prior history; pregnancy/breeding safety and young-puppy rules differ by jurisdiction.

Clinical practicality9.0/10

One palatable chew once monthly across six clear weight bands is highly practical; accurate weighing and use of the correct whole-tablet band remain essential.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Isoxazolines can be associated with tremor, ataxia and seizures, including in dogs without a prior seizure history; use particular caution with pre-existing neurologic disease.
  • Use only in dogs and only the correct whole-tablet weight band; do not split or extrapolate a strength to another species or band.
  • Age, pregnancy, lactation and breeding restrictions differ between current EU/UK and US labels; follow the locally applicable exact label and document the benefit-risk decision.
  • Confirm the parasite target and maintain the labelled monthly schedule; reassess breakthrough infestation, adherence and environmental reinfection rather than shortening intervals empirically.
Assessment sources
  1. VMD SPC 20242024
  2. FDA 20242024
  3. Simparica US flea field trial2016
  4. Simparica tick dose trials2016
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Sarolaner40 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Zoetis · United States
Manufacturer (register)
Zoetis Inc., United States
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 450, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა -40მგ საღეჭი ტაბლეტი 10-20კგ ძაღლებისთვის
№ 163-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-452
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
No dose for this species
This sarolaner product is for dogs only. Do not use it in cats.
 Cat Any weight By mouth - Product label (SPC)
1 tablet
Simparica 40 mg Chewable Tablets for Dogs >10–20 kg not recommended
 Dog 10–20 kg By mouth monthly Product label (SPC)
80 mg, Chewable tablet · Cat Any weight Cat Any weight No dose for this species
This sarolaner product is for dogs only. Do not use it in cats.
 - Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა - 80მგ საღეჭი ტაბლეტი 20-40კგ ძაღლებისთვის
№ 162-11
Verified on: 15 Oct 2026
80 mg, Chewable tablet · Dog 20–40 kg Dog 20–40 kg 1 tablet
Simparica 80 mg Chewable Tablets for Dogs >20–40 kg not recommended
 · monthly		 monthly Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა - 80მგ საღეჭი ტაბლეტი 20-40კგ ძაღლებისთვის
№ 162-11
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Simparica 80 mg, Chewable tablet

sarolaner 80 mg, chewable tablet for dogs 20-40 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.4/10
Very good
vetman assessment

Simparica

80 mg, sarolaner 80 mg, chewable tablet for dogs 20-40 kg
Assessed clinical scopeDog · Full labelled canine scope for monthly treatment and control of susceptible fleas, ticks and mites · By mouth
Care settingMonthly weight-band chewable ectoparasite control after age, neurologic and parasite-risk assessment
vetman score 8.4/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 162-11 · Verified on 15 Oct 2026

A strongly supported monthly canine ectoparasiticide with excellent efficacy and convenience; the main limitation is the class-wide neurological risk and jurisdiction-dependent age/breeding restrictions.

Regulatory and scientific credibility9.0/10

Every exact strength is registered in Georgia and the product has mature current EU/UK and FDA authorisations with detailed public labels.

Clinical efficacy9.0/10

Randomized controlled laboratory and multicentre field studies show high and persistent monthly efficacy against labelled flea, tick and mite targets, with clinically useful speed of kill.

Safety and tolerability7.0/10

Safety is well characterised, but sarolaner is an isoxazoline and rare tremor, ataxia or seizures can occur even without prior history; pregnancy/breeding safety and young-puppy rules differ by jurisdiction.

Clinical practicality9.0/10

One palatable chew once monthly across six clear weight bands is highly practical; accurate weighing and use of the correct whole-tablet band remain essential.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Isoxazolines can be associated with tremor, ataxia and seizures, including in dogs without a prior seizure history; use particular caution with pre-existing neurologic disease.
  • Use only in dogs and only the correct whole-tablet weight band; do not split or extrapolate a strength to another species or band.
  • Age, pregnancy, lactation and breeding restrictions differ between current EU/UK and US labels; follow the locally applicable exact label and document the benefit-risk decision.
  • Confirm the parasite target and maintain the labelled monthly schedule; reassess breakthrough infestation, adherence and environmental reinfection rather than shortening intervals empirically.
Assessment sources
  1. VMD SPC 20242024
  2. FDA 20242024
  3. Simparica US flea field trial2016
  4. Simparica tick dose trials2016
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Sarolaner80 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა - 80მგ საღეჭი ტაბლეტი 20-40კგ ძაღლებისთვის
№ 162-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-452
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
No dose for this species
This sarolaner product is for dogs only. Do not use it in cats.
 Cat Any weight By mouth - Product label (SPC)
1 tablet
Simparica 80 mg Chewable Tablets for Dogs >20–40 kg not recommended
 Dog 20–40 kg By mouth monthly Product label (SPC)
120 mg, Chewable tablet · Cat Any weight Cat Any weight No dose for this species
This sarolaner product is for dogs only. Do not use it in cats.
 - Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა - 120მგ საღეჭი ტაბლეტი 40-60კგ ძაღლებისთვის
№ 156-11
Verified on: 15 Oct 2026
120 mg, Chewable tablet · Dog 40–60 kg Dog 40–60 kg 1 tablet
Simparica 120 mg Chewable Tablets for Dogs >40–60 kg Use appropriate combination of available strengths to achieve the recommended dose of 2–4 mg/kg.
 · monthly		 monthly Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა - 120მგ საღეჭი ტაბლეტი 40-60კგ ძაღლებისთვის
№ 156-11
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Simparica 120 mg, Chewable tablet

sarolaner 120 mg, chewable tablet for dogs 40-60 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.4/10
Very good
vetman assessment

Simparica

120 mg, sarolaner 120 mg, chewable tablet for dogs 40-60 kg
Assessed clinical scopeDog · Full labelled canine scope for monthly treatment and control of susceptible fleas, ticks and mites · By mouth
Care settingMonthly weight-band chewable ectoparasite control after age, neurologic and parasite-risk assessment
vetman score 8.4/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 156-11 · Verified on 15 Oct 2026

A strongly supported monthly canine ectoparasiticide with excellent efficacy and convenience; the main limitation is the class-wide neurological risk and jurisdiction-dependent age/breeding restrictions.

Regulatory and scientific credibility9.0/10

Every exact strength is registered in Georgia and the product has mature current EU/UK and FDA authorisations with detailed public labels.

Clinical efficacy9.0/10

Randomized controlled laboratory and multicentre field studies show high and persistent monthly efficacy against labelled flea, tick and mite targets, with clinically useful speed of kill.

Safety and tolerability7.0/10

Safety is well characterised, but sarolaner is an isoxazoline and rare tremor, ataxia or seizures can occur even without prior history; pregnancy/breeding safety and young-puppy rules differ by jurisdiction.

Clinical practicality9.0/10

One palatable chew once monthly across six clear weight bands is highly practical; accurate weighing and use of the correct whole-tablet band remain essential.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Isoxazolines can be associated with tremor, ataxia and seizures, including in dogs without a prior seizure history; use particular caution with pre-existing neurologic disease.
  • Use only in dogs and only the correct whole-tablet weight band; do not split or extrapolate a strength to another species or band.
  • Age, pregnancy, lactation and breeding restrictions differ between current EU/UK and US labels; follow the locally applicable exact label and document the benefit-risk decision.
  • Confirm the parasite target and maintain the labelled monthly schedule; reassess breakthrough infestation, adherence and environmental reinfection rather than shortening intervals empirically.
Assessment sources
  1. VMD SPC 20242024
  2. FDA 20242024
  3. Simparica US flea field trial2016
  4. Simparica tick dose trials2016
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Sarolaner120 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა - 120მგ საღეჭი ტაბლეტი 40-60კგ ძაღლებისთვის
№ 156-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-452
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
No dose for this species
This sarolaner product is for dogs only. Do not use it in cats.
 Cat Any weight By mouth - Product label (SPC)
1 tablet
Simparica 120 mg Chewable Tablets for Dogs >40–60 kg Use appropriate combination of available strengths to achieve the recommended dose of 2–4 mg/kg.
 Dog 40–60 kg By mouth monthly Product label (SPC)
Active substance doses, with sources
Active substance Sarolaner
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
2–4 mg/kg Dog Maintenance By mouth monthly
VMD SPC 2024
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Simparica 5 mg chewable tablets for dogs 1.3-2.5 kg - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2024

Known Contraindications

  • Critical
    Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
    Sources: VMD SPC · VMD
  • Warning (Dog)
    The safety of the veterinary medicinal product has not been established during pregnancy and lactation or in animals intended for breeding. Pregnancy and lactation: The use in these animals is not recommended. Fertility: The use in breeding animals is not recommended. The safe use of SIMPARICA has not been evaluated in breeding, pregnant, or lactating dogs.
    Sources: VMD SPC · VMD · FDA
  • Warning (Dog)
    Pregnancy and lactation: The use in these animals is not recommended.
    Sources: VMD SPC · VMD
  • Warning (Dog)
    In the absence of available data, treatment of puppies less than 8 weeks of age and/or dogs less than 1.3 kg bodyweight should be based on a benefit-risk assessment by the responsible veterinarian. less than 1.25 kg
    Sources: VMD SPC · VMD
  • Warning (Dog)
    The minimum age for sarolaner depends on the product label. Some labels permit use from 8 weeks, while the US Simparica label restricts use to dogs at least 6 months old because younger puppies developed neurological signs at high multiples of the dose. Follow the selected product’s label.
    Sources: VMD SPC · VMD · FDA
  • Caution (Dog)
    Sarolaner is a member of the isoxazoline class. This class has been associated with neurologic adverse reactions including tremors, ataxia, and seizures. Seizures have been reported in dogs receiving isoxazoline class drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. mild tremors convulsions
    Sources: VMD SPC · VMD · FDA

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (80 more) Hide additional products

Same therapeutic group 80

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 16 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗